Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Split-Virion H5N1 Vaccine in Adolescents
NCT00900588Phase 2Completed
- Sponsor
- Sinovac Biotech Ltd.
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of split-virion pandemic influenza vaccine (H5N1) in Influenza A H5N1 infection (H5N1), sponsored by Sinovac Biotech Ltd.. Status: completed.
02
Drugs
split-virion pandemic influenza vaccine (H5N1)
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on NCT00900588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900588.